LOS ANGELES, October 2026 – BlackLight Surgical, a pioneer in intraoperative cancer detection technologies for interventional oncology, announced that results from a clinical study of its dye-free fluorescence imaging technology have been accepted for presentation at the 2027 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP), March 13–18, 2027, in Vancouver, British Columbia.
The abstract, titled “Label-Free Wide-Field Time-Resolved Fluorescence Imaging of Breadloafed Breast Specimens: Histopathologic Concordance and Potential to Guide Targeted Tissue Sampling at the Grossing Bench,” will be presented by the BlackLight team and collaborator Dr. Farnaz Dadmanesh, Associate Professor and Anatomic Pathologist in the Department of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center.
“We look forward to these results, which will demonstrate our technology’s performance in distinguishing cancer from benign breast tissue without adding a dye or a drug,” said Frank Cheng, CEO of BlackLight Surgical. “We are grateful to our clinical collaborators who led this work and thrilled that it will be shared with the world’s pathology community.”
In the study, breast lumpectomy specimens were prepared using routine pathology protocols. Tissue sections were imaged before formalin fixation with a wide-field scanning system that covers an 80 × 80 mm field at 125 μm resolution in under one minute per cassette. The technology maps the decay of the tissue’s own fluorescence, without stains or contrast agents, and a machine-learning algorithm was trained to distinguish malignant from benign tissue.
About BlackLight Surgical
BlackLight Surgical is a pioneer in intraoperative cancer detection technologies for interventional oncology. Developed in collaboration with Cedars-Sinai Medical Center, BlackLight’s system uses dye-free fluorescence imaging to identify cancerous tissue with high precision. The technology has received FDA Breakthrough Device designation. BlackLight’s mission is to help surgeons see cancer clearly during surgery so that patients can be treated successfully with a single operation. For more information, visit bls.life.